CN103417911A - 化疗辅助用中药组合物 - Google Patents
化疗辅助用中药组合物 Download PDFInfo
- Publication number
- CN103417911A CN103417911A CN2013102876398A CN201310287639A CN103417911A CN 103417911 A CN103417911 A CN 103417911A CN 2013102876398 A CN2013102876398 A CN 2013102876398A CN 201310287639 A CN201310287639 A CN 201310287639A CN 103417911 A CN103417911 A CN 103417911A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- radix
- herba
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 28
- 230000000694 effects Effects 0.000 claims abstract description 37
- 241001163443 Daphne giraldii Species 0.000 claims abstract description 15
- 241000222336 Ganoderma Species 0.000 claims abstract description 15
- 239000009636 Huang Qi Substances 0.000 claims abstract description 15
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 15
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 15
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 15
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 15
- 235000008434 ginseng Nutrition 0.000 claims abstract description 15
- 229910052957 realgar Inorganic materials 0.000 claims abstract description 15
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 15
- 241000746375 Andrographis Species 0.000 claims description 14
- 241000208340 Araliaceae Species 0.000 claims description 14
- 241001550206 Colla Species 0.000 claims description 14
- 241000209020 Cornus Species 0.000 claims description 14
- 244000293323 Cosmos caudatus Species 0.000 claims description 14
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 14
- 241000283956 Manis Species 0.000 claims description 14
- 241000131808 Scolopendra Species 0.000 claims description 14
- 241000219095 Vitis Species 0.000 claims description 14
- 239000008517 radix Trichosanthis Substances 0.000 claims description 14
- 230000008901 benefit Effects 0.000 abstract description 4
- 235000000336 Solanum dulcamara Nutrition 0.000 abstract description 2
- 241000031023 Amana edulis Species 0.000 abstract 1
- 244000118350 Andrographis paniculata Species 0.000 abstract 1
- 240000008564 Boehmeria nivea Species 0.000 abstract 1
- 244000157790 Buglossoides arvense Species 0.000 abstract 1
- 235000004256 Buglossoides arvense Nutrition 0.000 abstract 1
- 241000219357 Cactaceae Species 0.000 abstract 1
- 241000258920 Chilopoda Species 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 235000003398 Curcuma aromatica Nutrition 0.000 abstract 1
- 241001466453 Laminaria Species 0.000 abstract 1
- 240000001131 Nostoc commune Species 0.000 abstract 1
- 235000013817 Nostoc commune Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 240000004371 Panax ginseng Species 0.000 abstract 1
- 241000283966 Pholidota <mammal> Species 0.000 abstract 1
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract 1
- 241000193241 Solanum dulcamara Species 0.000 abstract 1
- 235000002594 Solanum nigrum Nutrition 0.000 abstract 1
- 240000002307 Solanum ptychanthum Species 0.000 abstract 1
- 241000218989 Trichosanthes Species 0.000 abstract 1
- 235000007212 Verbena X moechina Moldenke Nutrition 0.000 abstract 1
- 240000001519 Verbena officinalis Species 0.000 abstract 1
- 235000001594 Verbena polystachya Kunth Nutrition 0.000 abstract 1
- 235000007200 Verbena x perriana Moldenke Nutrition 0.000 abstract 1
- 235000002270 Verbena x stuprosa Moldenke Nutrition 0.000 abstract 1
- 240000006365 Vitis vinifera Species 0.000 abstract 1
- 239000003292 glue Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- 230000006870 function Effects 0.000 description 29
- 239000008280 blood Substances 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 24
- 210000004185 liver Anatomy 0.000 description 16
- 231100000614 poison Toxicity 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- 230000036407 pain Effects 0.000 description 14
- 238000001990 intravenous administration Methods 0.000 description 13
- 206010007247 Carbuncle Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 235000009508 confectionery Nutrition 0.000 description 10
- 230000036461 convulsion Effects 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 206010010904 Convulsion Diseases 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 239000003440 toxic substance Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 206010047700 Vomiting Diseases 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
- 206010023126 Jaundice Diseases 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 229960002949 fluorouracil Drugs 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000013521 mastic Substances 0.000 description 6
- 230000007096 poisonous effect Effects 0.000 description 6
- 238000004064 recycling Methods 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 206010000077 Abdominal mass Diseases 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 206010017553 Furuncle Diseases 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- 206010065553 Bone marrow failure Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 208000004680 Rectal Fistula Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 206010002156 anal fistula Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 4
- 235000008207 calcium folinate Nutrition 0.000 description 4
- 239000011687 calcium folinate Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 208000001780 epistaxis Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010010071 Coma Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 201000000297 Erysipelas Diseases 0.000 description 3
- 206010027514 Metrorrhagia Diseases 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 206010067171 Regurgitation Diseases 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 208000002474 Tinea Diseases 0.000 description 3
- 206010044302 Tracheitis Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 208000002399 aphthous stomatitis Diseases 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 208000002894 beriberi Diseases 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229940126701 oral medication Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 231100000019 skin ulcer Toxicity 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 206010055000 Bromhidrosis Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010052369 Encephalitis lethargica Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000371997 Eriocheir sinensis Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010060710 Galactostasis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000244155 Taenia Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 201000010582 ecthyma Diseases 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000013007 heat curing Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 201000008585 noma Diseases 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229960003349 pemetrexed disodium Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种化疗辅助用中药组合物,其包括:穿山甲、黄芪、郁金、葡萄叶、人参、乌药、虎杖、牛黄,海带、地耳、仙人掌、珍珠、雄黄、藏红花、蜈蚣、白英、天花粉、龙葵、生地黄、马鞭草、白芍、灵芝、三棱、吴茱萸、紫草、穿心莲、鹿角胶、光慈姑、祖师麻、苎麻根。采用这种中药组合物对化疗引起的副作用的治疗具有疗效快,有效率高,副作用小等优点。
Description
技术领域
本发明涉及一种中药组合物,尤其涉及一种用于治疗化疗引起的副作用的中药组合物。
背景技术
肿瘤的有效治疗迄今仍主要是手术、化疗、放疗,然而,有80%的病人要通过化疗、放疗获得更长时间的生存。然而化疗引起的如骨髓移植、免疫力低下、胃肠道反应等毒副反应,使患者难以坚持。化疗药物引起的全身症状包括头晕、疲乏无力、精神萎靡、食欲不佳、失眠多梦、口干津少、大小便失调等。如辅以中药治疗即可以增加疗效,又能在一定程度上避免或减轻放化疗的毒副反应,延长患者的生存期和生存质量。现有的中药方剂主要通过以下四个方面对上述副作用进行调理:1.补血填精:2.益气固本,提高免疫力:3.和胃降逆:减轻恶心、呕吐等胃肠道反应;4.健脾益肾。上述副作用也可以总结为4大类:1.消化道反应:消化道粘膜细胞常受到多种化疗药物的损伤,引起一系列的消化道反应,一般较骨髓抑制出现的早。如:食欲减退、恶心呕吐、腹痛腹泻等等是脾胃失和、升降失司的表现,中医治疗主要以健脾和胃、降逆止吐为主,药物有:党参、白术、竹菇等。2.骨髓抑制:多数的抗肿瘤药物均可引起不同程度的骨髓抑制,主要表现为外周血白细胞的下降,以中性粒细胞下降为主,有的药物使血小板下降明显。较严重的情况下,可以给予粒细胞集落刺激因子,但骨髓抑制重恢复缓慢的患者加用中药治疗后可以缩短血象恢复的时间。药物:女贞子、山萸肉等。3.免疫抑制:晚期肿瘤患者的免疫反应较正常人低,而多数抗肿瘤药物又对机体的免疫状态有不同程度的影响。肿瘤、机体免疫功能状态及药物治疗间相互作用是很复杂的。药物在杀灭肿瘤细胞的同时抑制了机体的免疫功能,后者又为肿瘤细胞 的扩散提供了条件。所以用中医药调整既保护了机体的免疫功能和抗病能力,有在一定程度上抑制了肿瘤的生长。4.神经损伤:一些植物碱类的药物存在神经毒性。如长春新碱、紫杉醇,可以引起肢体麻木、全身无力、膝腱反射低下,肠麻痹、便秘、共济失调等。治疗常用:络石藤、鸡血藤等。
为了减缓或消除上述副作用,使用中药来治疗化疗引起的副作用取得了一定的效果,但仍需要更有效的方剂,以能够满足疗效快,有效率高,副作用小的需求。
发明内容
本发明所要解决的技术问题是在于提供一种新型的用于治疗化疗引起的副作用的中药组合物及其制备方法,采用这种中药组合物对用于治疗化疗引起的副作用的治疗具有疗效快,有效率高,副作用小的需求等优点。
为了解决上述技术问题,本发明提供了一种用于治疗化疗引起的副作用的中药组合物,其包括:穿山甲、黄芪、郁金、葡萄叶、人参、乌药、虎杖、牛黄,海带、地耳、仙人掌、珍珠、雄黄、藏红花、蜈蚣、白英、天花粉、龙葵、生地黄、马鞭草、白芍、灵芝、三棱、吴茱萸、紫草、穿心莲、鹿角胶、光慈姑、祖师麻、苎麻根。
其中,各种组份的重量份数比为,穿山甲10-40重量份、黄芪10-40重量份、郁金5-10重量份、葡萄叶5-25重量份、人参5-20重量份、乌药10-20重量份、虎杖10-20重量份、牛黄10-15重量份,海带10-30重量份、地耳10-25重量份、仙人掌10-20重量份、珍珠10-15重量份、雄黄5-10重量份、藏红花10-20重量份、蜈蚣10-15重量份、白英10-15重量份、天花粉5-10重量份、龙葵5-10重量份、生地黄10-25重量份、马鞭草10-15重量份、白芍10-25重量份、灵芝10-25重量份、三棱10-25重量份、吴茱萸10-25重 量份、紫草10-20重量份、穿心莲10-20重量份、鹿角胶10-25重量份、光慈姑10-15重量份、祖师麻10-15重量份、苎麻根10-15重量份。
其中,所述中药组合药物剂型可以为汤剂、散剂、蜜炼丸剂、水合丸剂、片剂、胶囊、口服液、颗粒剂、胶剂或糖浆剂。
为解决上述技术问题,本发明还提供了不同剂型的上述中药组合物的制备方法:
散剂的制备方法:称取原料、原料药粉碎、过筛后,充分混匀制成散剂。
颗粒剂的制备方法:第一步,将所述中药组合物添加剂中各组分按比例混合,获得混合物,加入相对于混合物质量2~4倍的水,进行煎煮处理1~3小时,将煎煮液进行过滤,浓缩处理,获得去除水分的膏体,将获得的膏体中加入相对于第一步混合物质量3~5倍的醇浓度为65%~75%的乙醇,进行搅拌20分钟~40分钟,在0~4℃下冷藏1~2小时,过滤,减压回收乙醇,获得干膏,烘干、粉碎成20目~200目的粉末,获得中药组合物添加剂颗粒。
粉剂的制备方法:将所述中药组合物添加剂中各组分按比例混合,获得混合物,将原药材混合物粉碎后,先用乙醇将药材浸泡2小时后,乙醇回流提取2次,每次2小时,合并滤液并浓缩成稠膏状;滤渣再用水提取2次,第一次提取2.5小时,第二次提取1.5小时,过滤,合并滤液并浓缩成稠膏状;合并浸膏,最后加入适量淀粉和糊精(或其它辅料),混合均匀,烘干,粉碎,即制备成粉剂。
汤剂制备方法:将所述中药组合物添加剂中各组分按比例混合,获得混合物,将原药材混合物粉碎后,用水将药材浸泡1-2小时后,然后用武火煎煮至沸腾,再用文火煎煮30分钟,过滤,滤渣加水用文火煎煮两次,每次1小时。合并滤液,将滤液浓缩后加入乙醇至滤液中乙醇含量为70%,过滤,滤液回收乙醇,浓缩,过滤、灌封、灭菌,即制备成口服液。
针剂制备方法:将所述中药组合物添加剂中各组分按比例混合,获得混 合物,将原药材混合物粉碎后,用水将药材浸泡1-2小时后,然后用火煎煮至沸腾,再用小火煎煮30分钟,过滤,滤渣用小火煎煮两次,每次1小时。合并滤液,将滤液浓缩后加入乙醇至滤液中乙醇含量为70%,过滤,滤液回收乙醇,浓缩,冷藏、过滤、精滤、灌封、灭菌,即制备成注射剂。
为解决上述技术问题,本发明还提供了上述的中药组合物在制备用于治疗化疗引起的副作用的药品中的应用。
本发明的有益效果:
相对于现有技术中的用于治疗化疗引起的副作用的药物,采用这种中药组合物对化疗引起的副作用的治疗具有疗效快,有效率高,副作用小等优点。
具体实施方式
本发明提供了一种用于治疗化疗引起的副作用的中药组合物,其包括:穿山甲、黄芪、郁金、葡萄叶、人参、乌药、虎杖、牛黄,海带、地耳、仙人掌、珍珠、雄黄、藏红花、蜈蚣、白英、天花粉、龙葵、生地黄、马鞭草、白芍、灵芝、三棱、吴茱萸、紫草、穿心莲、鹿角胶、光慈姑、祖师麻、苎麻根。
穿山甲,性味咸,凉,入肝、胃经,功用主治,消肿溃痈,搜风活络,通经下乳。治痈疽疮种,风寒湿痹,月经停闭,乳汁不通。外用止血。
黄芪,性温,味甘。功能主治:补气固表,托毒排脓,利尿,生肌。用于气虚乏力、久泻脱肛、自汗、水肿、子官脱垂、慢性肾炎蛋白尿、糖尿病、疮口久不愈合。
郁金,味辛苦,凉。入心、肺、肝经。功用主治:行气解郁,凉血破瘀。治胸腹胁肋诸痛,失心癫狂,热病神昏,吐血,衄血,尿血,血淋,妇女倒经,黄疸。
复叶葡萄叶,味甘;微涩;性凉,别名,止血灵;甜茶叶,功效:止血;清热解暑,主治:外伤出血;预防中暑。
人参,,味甘微苦,温。,脾、肺经。功用主治:大补元气,固脱生津,安神。治劳伤虚损,食少,倦怠,反胃吐食,大便滑泄,虚咳喘促,自汗暴脱,惊悸,健忘,眩晕头痛,阳痿,尿频,消渴,妇女崩漏,小儿慢惊,及久虚不复,一切气血津液不足之证。
乌药,性辛,温。入脾、肺、肾、膀胱经。功用主治:顺气,开郁,散寒,止痛。治气逆胸腹胀痛,宿食不消,反胃吐食,寒疝,脚气,小便频数。
虎杖,性味,苦,平。功用主治:祛风,利湿,破瘀,通经。治风湿筋骨疼痛,湿热黄疸,淋浊带下,妇女经闭,产后恶露不下,百瘕积聚,痔漏下血。跌扑损伤,烫伤,恶疮癣疾。
牛黄,性味苦甘,凉。入心、肝经。功用主治:清心,化痰,利胆,镇惊。治热病神昏、谵语,癫痫发狂,小儿惊风抽搐,牙疳,喉肿,口舌生疮,痈疽,疔毒。
海带,性味咸,寒。功用主治:软坚化痰,利水泄热。治瘿瘤结核,疝瘕,水肿,脚气。
地耳草,性味,苦甘,凉。功用主治:清热利湿,消肿解毒。治传染性肝炎,泻痢,小儿惊风,疳积,喉蛾,肠痈,疖肿,蛇咬伤。
仙人掌,性味苦,寒。入心、肺、胃三经。功用主治:行气活血,清热解毒。治心胃气痛,痞块,痢疾,痔血,咳嗽,喉痛,肺痈,乳痈,疔疮,汤火伤,蛇伤。
珍珠,性味甘咸,寒。入心、肝经。功用主治:镇心安神,养阴熄风,清热坠痰,去翳明目,解毒生肌。治惊悸,怔忡,癫痫,惊风搐搦,烦热消渴,喉痹口疳,目生翳障,疮疡久不收口。
雄黄,味辛苦,温,有毒。入心、肝、胃经。功用主治:燥湿,祛风,杀 虫,解毒。治疥癣,秃疮,痈疽,走马牙疳,缠腰蛇丹,破伤风,蛇虫蟹伤,腋臭,臁疮,哮喘,喉痹,惊痫,痔瘘。
藏红花,性味,甘,平。入心、肝经。功用主治:活血化瘀,散郁开结。治忧思郁结,胸膈痞闷,吐血,伤寒发狂,惊怖恍惚,妇女经闭,产后瘀血腹痛,跌扑肿痛。
蜈蚣,味辛,温,有毒。入肝经。功用主治:祛风,定惊,攻毒,散结。治中风,惊痫,破伤风,百日咳,瘰疬,结核,百积瘤块,疮疡肿毒,风癣,白秃,痔漏,烫伤。
白英,性寒,味甘;有小毒。功能主治:清热解毒,祛风利湿,化瘀。用于湿热黄疸、风热头痛、白带过多、风湿性关节炎。
天花粉,味甘苦酸,凉。入肺、胃经。功用主治:生津,止渴,降火,润燥,排脓,消肿。治热病口渴,消渴,黄疸,肺燥咳血,痈肿,痔瘘。
龙葵,味苦,寒。功用主治:清热,解毒,活血,消肿。治疔疮,痈肿,丹毒,跌打扭伤,慢性气管炎,急性肾炎。用于疮痈肿毒、皮肤湿疹、小便不利、老年慢性气管炎、白带过多、前列腺炎、痢疾。
马鞭草,味苦,凉.入肝、脾经。功用主治:清热解毒,活血散瘀,利水消肿。治外感发热,湿热黄疸,水肿,痢疾,疟疾,白喉,喉痹,淋病,经闭,百瘕,痈肿疮毒,牙疳。
生地黄,味甘苦,寒。入心、肝、肾经。功用主治:清热,凉血,生津。治温病伤阴,大热烦渴,舌绛,神昏,斑疹,吐血,衄血,虚劳骨蒸,咳血,消渴,便秘,血崩。
白芍,味苦酸,凉。入肝、脾经。功用主治:养血柔肝,缓中止痛,敛阴收汗。治胸腹胁肋疼痛,泻痢腹痛,自汗盗汗,阴虚发热,月经不调,崩漏,带下。
灵芝,性温,味淡。功能主治:滋补强壮。用于健脑、消炎、利尿、益肾。
三棱,味苦辛,平。入肝。脾经。功用主治:破血,行气,消积,止痛。治百瘕积聚,气血凝滞,心腹疼痛,胁下胀疼,经闭,产后瘀血腹痛,跌打损伤。疮肿坚硬。
吴茱萸,味辛苦,温,有毒。入肝、胃经。功用主治:温中,止痛,理气,燥湿,治呕逆吞酸,厥阴头痛,脏寒吐泻,脘腹胀痛,经行腹痛,五更泄泻,高血压症,脚气,疝气,口疮溃疡,齿痛,湿疹,黄水疮。
紫草,味苦,寒。入心包络、肝经。功用主治:凉血,活血,清热,解毒。治温热斑疹,湿热黄疸,紫癜,吐、衄、尿血,淋浊,热结便秘,烧伤,湿疹,丹毒,痈疡。
穿心莲,味苦,性寒,无毒。入心、肺二经。功用主治:清热解毒,凉血消肿。治急性菌痢,胃肠炎,感冒,流脑,气管炎,肺炎,百日咳,肺结核,肺脓疡,胆囊炎,高血压,鼻衄,口咽肿痛,疮疖痈肿,水火烫伤,毒蛇咬伤。
鹿角胶,味甘咸,温。入肝、肾经。功用主治:补血,益精。治肾气不足,虚劳羸瘦,腰痛,阴疽,男子阳痿、滑精,妇女子宫虚冷,崩漏,带下。
光慈姑,味甘,寒,有毒。功用主治:散结,化瘀。治咽喉肿痛,瘰疬,痈疽,疮肿,产后瘀滞。
祖师麻,味辛苦,温,有小毒。功用主治:祛风除湿,止痛散瘀。治风湿痹痛,四肢麻木,头痛,胃痛,跌打损伤。
苎麻根,味甘、寒、无毒。主治:咳嗽痰哮,小便不通,小便血淋,妊娠胎动,肛门肿痛,脱肛不收,背痈初起,丹毒,刀伤折损。
进一步优选,所述化疗引起的副作用的中药组合物仅由上述组分构成。
其中,各种组份的重量份数比可优选为:穿山甲15-40重量份、黄芪10-40重量份、郁金5-10重量份、葡萄叶5-20重量份、人参5-15重量份、乌药10-20重量份、虎杖10-15重量份、牛黄10-15重量份,海带10-30重 量份、地耳10-25重量份、仙人掌10-15重量份、珍珠10-15重量份、雄黄5-10重量份、藏红花10-15重量份、蜈蚣10-12重量份、白英10-15重量份、天花粉5-10重量份、龙葵5-10重量份、生地黄15-25重量份、马鞭草10-15重量份、白芍10-25重量份、灵芝10-15重量份、三棱10-25重量份、吴茱萸10-25重量份、紫草10-15重量份、穿心莲10-15重量份、鹿角胶10-25重量份、光慈姑10-15重量份、祖师麻10-15重量份、苎麻根10-15重量份。
进一步,各种组份的重量份数比也可优选为:穿山甲20-25重量份、黄芪20-30重量份、郁金5-8重量份、葡萄叶10-20重量份、人参5-10重量份、乌药10-15重量份、虎杖10-15重量份、牛黄10-15重量份,海带10-30重量份、地耳10-15重量份、仙人掌10-15重量份、珍珠10-15重量份、雄黄5-10重量份、藏红花10-15重量份、蜈蚣10-12重量份、白英10-12重量份、天花粉5-10重量份、龙葵5-10重量份、生地黄15-20重量份、马鞭草10-15重量份、白芍10-15重量份、灵芝10-15重量份、三棱10-15重量份、吴茱萸10-15重量份、紫草10-15重量份、穿心莲10-15重量份、鹿角胶10-15重量份、光慈姑10-15重量份、祖师麻10-15重量份、苎麻根10-15重量份。
以下采用实施例来详细说明本发明的实施方式,借此对本发明如何应用技术手段来解决技术问题,并达成技术效果的实现过程能充分理解并据以实施。
实施例1本发明中药组合物颗粒1的制备
将穿山甲20g、黄芪20g、郁金5g、葡萄叶10g、人参5g、乌药10g、虎杖10g、牛黄10g,海带10g、地耳10g、仙人掌10g、珍珠10g、雄黄5g、藏红花10g、蜈蚣10g、白英10g、天花粉g、龙葵5g、生地黄15g、马鞭草10g、白芍10g、灵芝10g、三棱10g、吴茱萸10g、紫草g、穿心莲10g、鹿角胶10g、光慈姑10g、祖师麻10g、苎麻根10g。混合并粉碎;加入相对于混合物质量2000ml的水,进行煎煮处理2小时, 将煎煮液进行过滤,浓缩处理,获得去除水分的膏体,将获得的膏体中加入2000ml的醇浓度为65%~75%的乙醇,进行搅拌30分钟,在0~4℃下冷藏1.5小时,过滤,减压回收乙醇,加入适量药用糊精混合均匀,制粒,烘干,粉碎成100目的粉末,制成颗粒剂(每1g相当于原生药2g)。
实施例2本发明中药组合物颗粒2的制备
穿山甲25g、黄芪30g、郁金8g、葡萄叶20g、人参10g、乌药15g、虎杖15g、牛黄15g,海带30g、地耳15g、仙人掌15g、珍珠15g、雄黄10g、藏红花15g、蜈蚣12g、白英12g、天花粉10g、龙葵10g、生地黄20g、马鞭草15g、白芍15g、灵芝15g、三棱15g、吴茱萸15g、紫草15g、穿心莲15g、鹿角胶15g、光慈姑15g、祖师麻15g、苎麻根15g。混合并粉碎;加入相对于混合物质量1500ml的水,进行煎煮处理2小时,将煎煮液进行过滤,浓缩处理,获得去除水分的膏体,将获得的膏体中加入2000ml的醇浓度为65%~75%的乙醇,进行搅拌30分钟,在0~4℃下冷藏1.5小时,过滤,减压回收乙醇,加入适量药用糊精混合均匀,制粒,烘干,粉碎成100目的粉末,制成颗粒剂(每1g相当于原生药2g)。
实施例3本发明中药组合物注射剂的制备
穿山甲22g、黄芪25g、郁金5g、葡萄叶15g、人参5g、乌药10g、虎杖12g、牛黄10g,海带10g、地耳10g、仙人掌10g、珍珠10g、雄黄6g、藏红花12g、蜈蚣10g、白英11g、天花粉7g、龙葵8g、生地黄15g、马鞭草10g、白芍12g、灵芝10g、三棱10g、吴茱萸12g、紫草10g、穿心莲10g、鹿角胶13g、光慈姑10g、祖师麻14g、苎麻根10g。混合并粉碎;用3500水将药材浸泡2小时后,然后用火煎煮至沸腾,再用小火煎煮30分钟,过滤,滤渣用小火煎煮两次,每次1小时。合并滤液,将滤液浓缩后加入乙醇至滤液中乙醇含量为70%,过滤,滤液回收乙醇,浓 缩至每1ml相当于原生药1g,冷藏、过滤、精滤、灌封、灭菌,即制备成注射剂。
实施例4毒性试验
急性毒性试验
(1)试验准备
A、选昆明小白鼠60只,重量为18-22g(雌雄各30只)
B、试验样品的处理:取30g本发明所述中药组合物颗粒1,加入蒸馏水50ml,经研磨而成含量为600mg/ml全浆备用。
(2)口服法:取昆明小白鼠30只(雌雄各15只),重量为18-22g/只,每只小白鼠给予样品均浆液0.5ml灌胃,共给予两次(间隔时间为4小时),总剂量为1ml,观察10天,小白鼠均健康生存,无任何毒副反应,经解剖观察血象、肝功能、各脏器组织形态学所见与对照组比较无差异。
(3)注射法:取昆明小白鼠30只(雌雄各15只),重量为18-22g/只,每只小白鼠给予本发明所述的中药组合物注射剂0.25ml肌肉注射,共给予两次(间隔时间为4小时),总剂量为0.5ml。观察10天,小白鼠均健康生存,无任何毒副反应,经解剖观察血象、肝功能、各脏器组织形态学所见与对照组比较无差异。
2、蓄积性毒性试验
(1)试验准备
A、选大白鼠6-8周龄30只(雌雄各15只);
B、试验样品的处理:取30g本发明所述中药组合物颗粒1,加入蒸馏水50ml,经研磨成细浆,可加入1%的右羧甲基纤维素纳助悬,制成含量为600mg/ml的均浆备用。
(2)口服法:取大白鼠30只(雌雄各15只),分三个剂量组,按随机选取的 大白鼠分成三个组,每组10只,(雌雄各5只),分别给予每只大白鼠每天0.4ml、0.25ml、0.1ml的样品均浆灌胃,观察30天,大白鼠均健康生存,无任何毒副反应,经解剖观察血象、肝功能、各脏器组织形态所见与对照组比较无差异,大白鼠体内无积蓄。
上述结果说明:本发明所述的药物制剂对用于人体临床的药物是安全的,它无毒、无副作用、无积蓄。
实施例5具体临床实验
本组72例患者,均为住院病历,经过细胞学确诊为恶性肿瘤,全身体力评分(KPS评分)>70分,预计生存期>6月,血常规、肝肾功、心功能均正常,无明显化疗禁忌。随机分为两组:观察组36例,初治24例,复治12例,其中男性为23例,女性为13例;年龄34-69岁,平均年龄49.8岁。对照组36例,初治20例,复治16例,其中男性为20例,女性为16例;年龄35-71岁,平均年龄46.9岁。两组的性别、年龄、病理类型、既往诊治情况及KPS评分经过统计学处理(均应用统计软件SPSS16.0),无显著性差异,具有可比性。
两组具体情况如下表:
治疗方法:肺癌(全部为非小细胞病人,包括两种类型:腺癌、鳞癌)病人,腺癌病人采用培美曲塞二钠(Pem)500mg/m2静脉滴注第1天,顺铂(DDP)25mg/m2静脉滴注第1-3天。每3周重复一次。鳞癌病人应用吉西他滨(GEM)1000mg/m2静脉滴注第1、8天,顺铂(DDP)25mg/m2静脉滴注第1-3天。每3周重复。乳腺癌(均为术后辅助治疗)采用CAF方案:环磷酰胺(CTX)500mg/m2静脉滴注第1天,阿霉素(ADM)50mg/m2静脉滴注第1天,氟尿嘧啶(5-FU)500mg/m2静脉滴注第1、8天,每3周重复。结肠癌及胃癌采用OLF方案:奥沙利铂(L-OHP)85mg/m2静脉滴注第1天,亚叶酸钙(CF)200mg/m2静脉滴注第1-5天,氟尿嘧啶(5-FU)350mg/m2静脉滴注第1-5天,每3周重复。食管癌采用PF方案:顺铂(DDP)20mg/m2静脉滴注第1-5天,亚叶酸钙(CF)200mg/m2静脉滴注第1-5天,氟尿嘧啶(5-FU)350mg/m2静脉滴注第1-5天,每3周重复。两组患者均用上述方案联合化疗,并常规应用5-羟色胺受体拮抗剂止吐,观察组在化疗后口服中药治疗(中药组合物颗粒2,0.1g/kg),与化疗同时进行,连用14天,停7天,在第2周期化疗开始时进行第2次口服用药,应用2周期以上。以上病人均在化疗2-3周期后评价疗效。
观察指标:近期疗效参照RECIST1.0实体瘤疗效评价标准;毒副作用根据WHO标准,主要观察胃肠道症状、血常规变化、肝肾功能变化。结果如下表:
近期有效率:
治疗结果:近期疗效:观察组病灶完全缓解及部分缓解共24例,有效率为66.7%,对照组为22例,有效率为61.1%,两者无统计学差异。(P>0.05)
化疗的毒副作用发生率:两组的毒副作用发生率见下表:
观察组恶心、呕吐、白细胞减少、肝功损伤的发生率明显低于对照组(P<0.05),口腔炎及腹泻的发生率也低于对照组,但无统计学差异(P>0.05)。两者的肾功损伤均少见,无明显差异(P>0.05)。
因此药物对消化系统肿瘤、呼吸系统肿瘤、乳腺癌等恶性肿瘤化疗中,可以起到辅助治疗的作用,减少化疗期间不良反应,健脾益肾的功效。
根据本发明的进一步实施方式的其它改进和变型按照上述教导是可行的。以上所述,仅是本发明的较佳实施例而已,并非是对本发明作其它形式的限制,任何熟悉本专业的技术人员可能利用上述揭示的技术内容加以变更或改型为等同变化的等效实施例。但是凡是未脱离本发明技术方案内容,依 据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与改型,仍属于本发明技术方案的保护范围。由此,可理解的是,在所附权利要求的范围内,本发明可以除本文具体描述之外的方式实施。
Claims (6)
1.一种用于治疗化疗引起的副作用的中药组合物,其特征在于,包括:穿山甲、黄芪、郁金、葡萄叶、人参、乌药、虎杖、牛黄,海带、地耳、仙人掌、珍珠、雄黄、藏红花、蜈蚣、白英、天花粉、龙葵、生地黄、马鞭草、白芍、灵芝、三棱、吴茱萸、紫草、穿心莲、鹿角胶、光慈姑、祖师麻、苎麻根。
2.如权利要求1所述的中药组合物,其中,中药组合物包括穿山甲10-40重量份、黄芪10-40重量份、郁金5-10重量份、葡萄叶5-25重量份、人参5-20重量份、乌药10-20重量份、虎杖10-20重量份、牛黄10-15重量份,海带10-30重量份、地耳10-25重量份、仙人掌10-20重量份、珍珠10-15重量份、雄黄5-10重量份、藏红花10-20重量份、蜈蚣10-15重量份、白英10-15重量份、天花粉5-10重量份、龙葵5-10重量份、生地黄10-25重量份、马鞭草10-15重量份、白芍10-25重量份、灵芝10-25重量份、三棱10-25重量份、吴茱萸10-25重量份、紫草10-20重量份、穿心莲10-20重量份、鹿角胶10-25重量份、光慈姑10-15重量份、祖师麻10-15重量份、苎麻根10-15重量份。
3.如权利要求1所述的中药组合物,其中,中药组合物包括穿山甲15-40重量份、黄芪10-40重量份、郁金5-10重量份、葡萄叶5-20重量份、人参5-15重量份、乌药10-20重量份、虎杖10-15重量份、牛黄10-15重量份,海带10-30重量份、地耳10-25重量份、仙人掌10-15重量份、珍珠10-15重量份、雄黄5-10重量份、藏红花10-15重量份、蜈蚣10-12重量份、白英10-15重量份、天花粉5-10重量份、龙葵5-10重量份、生地黄15-25重量份、马鞭草10-15重量份、白芍10-25重量份、灵芝10-15重量份、三棱10-25重量份、吴茱萸10-25重量份、紫草10-15重量份、穿心莲10-15重量份、鹿角胶10-25重量份、光慈姑10-15重量份、祖师麻10-15重量份、苎麻根10-15重量份。
4.如权利要求1所述的中药组合物,其中,中药组合物包括穿山甲20-25重量份、黄芪20-30重量份、郁金5-8重量份、葡萄叶10-20重量份、人参5-10重量份、乌药10-15重量份、虎杖10-15重量份、牛黄10-15重量份,海带10-30重量份、地耳10-15重量份、仙人掌10-15重量份、珍珠10-15重量份、雄黄5-10重量份、藏红花10-15重量份、蜈蚣10-12重量份、白英10-12重量份、天花粉5-10重量份、龙葵5-10重量份、生地黄15-20重量份、马鞭草10-15重量份、白芍10-15重量份、灵芝10-15重量份、三棱10-15重量份、吴茱萸10-15重量份、紫草10-15重量份、穿心莲10-15重量份、鹿角胶10-15重量份、光慈姑10-15重量份、祖师麻10-15重量份、苎麻根10-15重量份。
5.如权利要求1所述的中药组合物,其中,中药组合物包括组合物仅由穿山甲、黄芪、郁金、葡萄叶、人参、乌药、虎杖、牛黄,海带、地耳、仙人掌、珍珠、雄黄、藏红花、蜈蚣、白英、天花粉、龙葵、生地黄、马鞭草、白芍、灵芝、三棱、吴茱萸、紫草、穿心莲、鹿角胶、光慈姑、祖师麻、苎麻根组成。
6.权利要求1-5中任一项所述的在治疗化疗引起的副作用中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310287639.8A CN103417911B (zh) | 2013-07-10 | 2013-07-10 | 化疗辅助用中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310287639.8A CN103417911B (zh) | 2013-07-10 | 2013-07-10 | 化疗辅助用中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103417911A true CN103417911A (zh) | 2013-12-04 |
CN103417911B CN103417911B (zh) | 2015-03-25 |
Family
ID=49643651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310287639.8A Expired - Fee Related CN103417911B (zh) | 2013-07-10 | 2013-07-10 | 化疗辅助用中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103417911B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104491187A (zh) * | 2015-01-16 | 2015-04-08 | 孙士强 | 一种具有防辐射的外用软膏及其制备方法 |
CN105055868A (zh) * | 2015-07-21 | 2015-11-18 | 周善良 | 一种防治结肠癌化疗毒副反应的中药制剂 |
CN107569607A (zh) * | 2017-08-08 | 2018-01-12 | 张振亚 | 一种调理肿瘤放化疗副作用的保健品 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101112495A (zh) * | 2007-07-30 | 2008-01-30 | 牛昱翔 | 一种治疗肿瘤的中药 |
CN102327390A (zh) * | 2011-10-18 | 2012-01-25 | 周国生 | 一种防治化疗毒副反应的中药组方及其丸剂的制备方法 |
-
2013
- 2013-07-10 CN CN201310287639.8A patent/CN103417911B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101112495A (zh) * | 2007-07-30 | 2008-01-30 | 牛昱翔 | 一种治疗肿瘤的中药 |
CN102327390A (zh) * | 2011-10-18 | 2012-01-25 | 周国生 | 一种防治化疗毒副反应的中药组方及其丸剂的制备方法 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104491187A (zh) * | 2015-01-16 | 2015-04-08 | 孙士强 | 一种具有防辐射的外用软膏及其制备方法 |
CN104491187B (zh) * | 2015-01-16 | 2018-08-14 | 孙士强 | 一种具有防辐射的外用软膏及其制备方法 |
CN105055868A (zh) * | 2015-07-21 | 2015-11-18 | 周善良 | 一种防治结肠癌化疗毒副反应的中药制剂 |
CN107569607A (zh) * | 2017-08-08 | 2018-01-12 | 张振亚 | 一种调理肿瘤放化疗副作用的保健品 |
CN107569607B (zh) * | 2017-08-08 | 2021-01-08 | 张振亚 | 一种调理肿瘤放化疗副作用的组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103417911B (zh) | 2015-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105688159A (zh) | 一种制备治疗日光性皮炎的中药组合物的方法 | |
CN105920514A (zh) | 治疗代谢综合征的中药组合物 | |
CN103893738B (zh) | 一种抑制肿瘤生长中药组合物及其制备方法 | |
CN104524287A (zh) | 一种治疗过敏性紫癜的中药组合物及其制备方法 | |
CN103920034A (zh) | 减轻肿瘤病人化疗副反应的中药组合物及制法 | |
CN103417911B (zh) | 化疗辅助用中药组合物 | |
CN101518594B (zh) | 一种抗肿瘤及增强免疫力的中药制剂及其制备方法 | |
CN101564464B (zh) | 一种调节肿瘤患者机体免疫力的中药药物 | |
CN101904939A (zh) | 治疗年老血崩病的中草药 | |
CN104162093A (zh) | 治疗乳腺癌的中药制剂及其制备方法 | |
CN105381410A (zh) | 一种治疗肝炎的中药制剂 | |
CN104840773A (zh) | 治疗椎动脉型颈椎病的中药组合物及制法 | |
CN105147956A (zh) | 一种治疗急性消化性溃疡出血的中药及制备方法 | |
CN105106634A (zh) | 一种治疗急性阑尾炎的中药制剂及其应用 | |
WO2015149391A1 (zh) | 一种治疗慢性肠炎的中药制剂及其制备方法 | |
CN116115714B (zh) | 一种抗肿瘤中药组合物及其制备方法和应用 | |
CN103142917A (zh) | 一种治疗慢性肾功能衰竭的药物及其制备方法 | |
CN102614466A (zh) | 一种治疗肺腺癌的中药制剂 | |
CN107519261A (zh) | 一种治疗白血病的中药组合物及其制备方法 | |
CN105832823A (zh) | 一种用于治疗原发性肝癌的药物制剂及其用途 | |
CN105194484A (zh) | 一种防治卵巢癌的中药制剂及制法 | |
CN105664048A (zh) | 一种抑制胃癌细胞增殖的药物组合物及其应用 | |
CN105456933A (zh) | 一种活血化瘀、通经活络的中药及其制备方法 | |
CN105327327A (zh) | 一种治疗急性胆囊炎的药物及其制备方法 | |
CN105381416A (zh) | 一种治疗上消化道出血的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150325 Termination date: 20160710 |